Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Connexin-43 (Cx43), encoded by the GJA1 gene, is a critical transmembrane protein that forms gap junctions and hemichannels, facilitating direct intercellular communication and the exchange of small molecules (UniProt P17302). The trafficking machinery and protein-protein interfaces (PPIs) of Cx43 encompass the regulatory network of proteins—including ZO-1, tubulin, and various kinases—that control the life cycle of Cx43 from synthesis to degradation (Smyth et al., 2010, PubMed: 20816515). In many diseases, such as cardiac arrhythmia, chronic wounds, and certain cancers, the normal trafficking and localization of Cx43 are disrupted, leading to impaired cell-cell coupling or pathological hemichannel activity (Leybaert et al., 2017, PubMed: 28935886). Therapeutic interventions targeting these interfaces, such as the peptide αCT1 which disrupts the Cx43-ZO-1 interaction, aim to restore functional gap junctions or mitigate inflammatory signaling (Ghatnekar et al., 2009, PubMed: 19439490). These approaches represent a precision medicine strategy to modulate connexin function without globally blocking all channel activities, thereby reducing potential side effects. By focusing on specific PPIs, researchers hope to develop more selective treatments for conditions like heart failure and diabetic foot ulcers (O'Quinn et al., 2011, PubMed: 21148468).
Modulation of gap junctional intercellular communication (GJIC) through stabilization of Cx43 at the plasma membrane, inhibition of hemichannel opening, or competitive disruption of regulatory protein-protein interactions such as the Cx43-ZO-1 interface (Rhett et al., 2011, PubMed: 21737680).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction alpha-1 protein (Connexin-43) trafficking and protein-protein interfaces (Cx43 trafficking/PPIs).